Research Progress in Screening Metabolic Biomarkers of Lung Cancer Based on Mass Spectrometry Technology
ZHAO Yuewei1, MENG Fanyu1,2*, HUANG Lin1,2*
Early diagnosis of lung cancer can significantly improve patient prognosis and increase patient survival rate. The occurrence and development of lung cancer is accompanied by changes in metabolites in the body. Therefore, comprehensive detection of metabolic pathways in the body, combined with bioinformatics tools to analyze metabolic response changes, can efficiently screen lung cancer-related metabolic markers, which can help to detect lung cancer in its early stages. In recent years, various metabolic detection technologies have been developed for screening metabolic biomarkers in lung cancer. Among them, mass spectrometry technology has shown significant advantages in sensitivity, specificity, analysis speed, multi-index parallel detection, etc. Therefore, it plays an important role in cancer diagnosis, disease monitoring, and treatment. This article summarizes the latest research progress of mass spectrometry technology in the clinical diagnosis and treatment of lung cancer, and provides a systematic outlook on the prospects of applying mass spectrometry methodology to the discovery studies of biomarkers. Through an in-depth understanding of recent research, it is expected to further understand the metabolic characteristics of lung cancer and provide precise evaluation techniques for early diagnosis and treatment of lung cancer
CN
EN